Near haploidization is a genomic hallmark which defines a molecular subgroup of giant cell glioblastoma

Author:

Baker Tiffany G1,Alden Jay1,Dubuc Adrian M2,Welsh Cynthia T1,Znoyko Iya1,Cooley Linda D3,Farooqi Midhat S3,Schwartz Stuart4,Li Yvonne Y56,Cherniack Andrew D56,Lindhorst Scott M7,Gener Melissa1,Wolff Daynna J1,Meredith David M2ORCID

Affiliation:

1. Department of Pathology and Laboratory Medicine, Medical University of South Carolina, Charleston, South Carolina, USA

2. Department of Pathology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA

3. Department of Pathology and Laboratory Medicine, Children’s Mercy Hospital and University of Missouri-Kansas City School of Medicine, Kansas City, Missouri, USA

4. Cytogenetics Laboratory, Laboratory Corporation of America® Holdings, Research Triangle Park, North Carolina, USA

5. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA

6. Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA

7. Department of Neurosurgery, Medical University of South Carolina, Charleston, South Carolina, USA

Abstract

Abstract Background Giant cell glioblastoma (gcGBM) is a rare histologic subtype of glioblastoma characterized by numerous bizarre multinucleate giant cells and increased reticulin deposition. Compared with conventional isocitrate dehydrogenase (IDH)-wildtype glioblastomas, gcGBMs typically occur in younger patients and are generally associated with an improved prognosis. Although prior studies of gcGBMs have shown enrichment of genetic events, such as TP53 alterations, no defining aberrations have been identified. The aim of this study was to evaluate the genomic profile of gcGBMs to facilitate more accurate diagnosis and prognostication for this entity. Methods Through a multi-institutional collaborative effort, we characterized 10 gcGBMs by chromosome studies, single nucleotide polymorphism microarray analysis, and targeted next-generation sequencing. These tumors were subsequently compared to the genomic and epigenomic profile of glioblastomas described in The Cancer Genome Atlas (TCGA) dataset. Results Our analysis identified a specific pattern of genome-wide massive loss of heterozygosity (LOH) driven by near haploidization in a subset of glioblastomas with giant cell histology. We compared the genomic signature of these tumors against that of all glioblastomas in the TCGA dataset (n = 367) and confirmed that our cohort of gcGBMs demonstrated a significantly different genomic profile. Integrated genomic and histologic review of the TCGA cohort identified 3 additional gcGBMs with a near haploid genomic profile. Conclusions Massive LOH driven by haploidization represents a defining molecular hallmark of a subtype of gcGBM. This unusual mechanism of tumorigenesis provides a diagnostic genomic hallmark to evaluate in future cases, may explain reported differences in survival, and suggests new therapeutic vulnerabilities.

Funder

Children’s Mercy Cancer Center

Publisher

Oxford University Press (OUP)

Subject

Electrical and Electronic Engineering,Building and Construction

Reference28 articles.

1. Giant cell glioblastoma: a glioblastoma subtype with distinct epidemiology and superior prognosis;Kozak;Neuro Oncol.,2009

2. Treatment and survival of patients harboring histological variants of glioblastoma;Ortega;J Clin Neurosci.,2014

3. Prognostic factors and treatment patterns in the management of giant cell glioblastoma;Jin;World Neurosurg.,2019

4. TP53, ATRX alterations, and low tumor mutation load feature IDH-wildtype giant cell glioblastoma despite exceptional ultra-mutated tumors;Cantero;Neurooncol Adv.,2020

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3